The Food and Drug Administration (FDA) is offering a funding opportunity titled "Novel Approaches to Support Therapeutic Development in Ultra-Rare Cancers (U01) Clinical Trial Optional," aimed at fostering innovative strategies for therapeutic development in both pediatric and adult ultra-rare cancers, including specific molecularly-defined subsets of more common cancers. This initiative seeks to encourage new methodologies that can significantly advance the treatment landscape for these challenging conditions. The total estimated funding for this program is $500,000, with a maximum award ceiling of $500,000, and the FDA anticipates making one award under this cooperative agreement. Interested applicants, including foreign organizations and non-domestic components of U.S. organizations, must submit their proposals by April 5, 2024, and can direct inquiries to Zahara Graves at zahara.graves@fda.hhs.gov or by phone at 240-402-0151.